Relapse Risk Lower With Double CBT Than With Matched Sibling or Unrelated Transplant
There was no significant difference in transplant-related mortality or overall survival.
There was no significant difference in transplant-related mortality or overall survival.
Researchers sought to determine gene regulation patterns that may help predict response to CAR-T therapy in patients with acute lymphoblastic leukemia.
Researchers sought to determine risk factors for relapse in patients with ALL.
Researchers sought to determine whether blinatumomab followed by POMP maintenance chemotherapy would be safe and effective in older patients with B-ALL.
Response rates improved from 2000 to 2019, but the rate of treatment-related fatal toxicities remained stable.
Bortezomib improved event-free survival and overall survival in children and young adults with T-cell lymphoblastic lymphoma.
About 62% of patients achieved a complete response, and this included patients with high-risk cytogenetics.
From 2000 to 2019, overall survival progressively improved for patients with Ph+ ALL who had post-transplant relapse.
The estimated event-free survival rate was 28.6% at 2 years and 19.6% at 3 years.
A study suggests low platelet or low hemoglobin levels may be factors linked to COVID-19 mortality in patients with hematologic malignancies.